Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform
By
Linkai Li
Zhongyu Chen
Yunrui Yan
Lening Zhang
May 7, 2026
Clinical Scorecard: Utilizing Vaccinia Virus in Lung Cancer Treatment: Advances in Preclinical Research and Future Potential as a Systemic Immunotherapy Approach
At a Glance
Category Detail
Condition Lung Cancer Key Mechanisms Vaccinia virus selectively kills tumor cells, activates antitumor immunity, and reshapes tumor-immune interactions. Target Population Patients with non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Care Setting Oncology clinics and research settings.
Key Highlights
Vaccinia virus (VV) can modulate the tumor microenvironment and enhance immune responses. VV shows promise in converting 'cold' tumors into responsive ones for immunotherapy. Early clinical data in NSCLC indicate potential but highlight challenges in systemic delivery and immunosuppressive feedback. Guideline-Based Recommendations
Diagnosis
Consider immunotherapy options for patients with advanced lung cancer. Management
Explore VV as a combination therapy with immune checkpoint inhibitors. Monitoring & Follow-up
Assess immune response and tumor microenvironment changes during treatment. Risks
Monitor for rapid immunosuppressive feedback and potential systemic delivery issues. Patient & Prescribing Data
Patients with advanced lung cancer, particularly those resistant to current therapies.
VV may enhance antitumor immunity and improve outcomes in patients with limited treatment options.
Clinical Best Practices
Utilize VV in conjunction with immune checkpoint inhibitors for enhanced efficacy. Focus on engineering strategies to improve tumor targeting and immune modulation. Related Resources & Content
